telaprevir - Profile

What are the generic sources for telaprevir and what is the scope of patent protection?

Telaprevir is the generic ingredient in one branded drug marketed by Vertex Pharms and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Telaprevir has nineteen patent family members in twelve countries.

Summary for telaprevir

International Patents:	19
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for telaprevir

Constraining patent/regulatory exclusivity:

8,431,615

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for telaprevir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vertex Pharms	INCIVEK	telaprevir	TABLET;ORAL	201917-001	May 23, 2011		DISCN	No	No	8,431,615

Expired US Patents for telaprevir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vertex Pharms	INCIVEK	telaprevir	TABLET;ORAL	201917-001	May 23, 2011	7,820,671
Vertex Pharms	INCIVEK	telaprevir	TABLET;ORAL	201917-001	May 23, 2011	8,529,882

EU/EMA Drug Approvals for telaprevir

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Janssen-Cilag International N.V.	Incivo	telaprevir	EMEA/H/C/002313Incivo, in combination with peginterferon alfa and ribavirin, is indicated for the treatment of genotype-1 chronic hepatitis C in adult patients with compensated liver disease (including cirrhosis):who are treatment naïve;who have previously been treated with interferon alfa (pegylated or non-pegylated) alone or in combination with ribavirin, including relapsers, partial responders and null responders.	Withdrawn	no	no	no	2011-09-19

International Patents for telaprevir

Country	Patent Number	Title	Estimated Expiration
Taiwan	200630093	Dose forms
South Korea	20130063022	DOSE FORMS COMPRISING VX-950 AND THEIR DOSAGE REGIMEN
Malaysia	141025	DOSE FORMS
China	101068547	Dose forms comprising VX-950 and their dosage regimen
Russian Federation	2007119725	ЛЕКАРСТВЕННЫЕ ФОРМЫ
Taiwan	201424733	Dose forms

Supplementary Protection Certificates for telaprevir

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1320540	C 2012 005	Romania		PRODUCT NAME: TELAPREVIR SI TOATE FORMELE ECHIVALENTE TERAPEUTIC ALEACESTUIA, PRECUM SARURI SI/SAU SOLVATI ACCEPTABILI FARMACEUTIC SAU SOLVATI AI UNOR ASTFEL DE SARURI; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/720/001; DATE OF NATIONAL AUTHORISATION: 20110919; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/720/001; DATE OF FIRST AUTHORISATION IN EEA: 20110919
1320540	1290007-2	Sweden		PRODUCT NAME: TELAPREVIR OCH FARMACEUTISKT GODTAGBARA SALTER OCH/ELLER SOLVAT AV TELAPREVIR ELLER SOLVAT AV SADANA SALTER; REG. NO/DATE: EU/1/11/720/001 20110919
1320540	SPC/GB12/010	United Kingdom		PRODUCT NAME: TELAPREVIR OR PHARMACEUTICALLY ACCEPTABLE SALTS AND/OR SOLVATES OF TELAPREVIR OR SOLVATES OF SUCH SALTS.; REGISTERED: UK EU/1/11/720/001 20110919
1320540	PA2012003	Lithuania		PRODUCT NAME: TELAPREVIRUM; REGISTRATION NO/DATE: EU/1/11/720/001 20110919
1320540	12C0018	France		PRODUCT NAME: TELAPREVIR ET LES SELS ET/OU LES SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES DU TELAPREVIR OU LES SOLVATES DE TELS SELS; REGISTRATION NO/DATE: EU/1/11/720/001 20110919
1320540	C300518	Netherlands		PRODUCT NAME: TELAPREVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN/OF SOLVAAT DAARVAN, OF SOLVATEN VAN DERGELIJKE ZOUTEN; REGISTRATION NO/DATE: EU/1/11/720/001 2011190919

Telaprevir: Investment Scenario, Market Dynamics, and Financial Trajectory Analysis

Last updated: February 3, 2026

---

Summary

Telaprevir is a hepatitis C virus (HCV) protease inhibitor developed by Vertex Pharmaceuticals, approved in 2011 for genotype 1 hepatitis C. The drug's market trajectory was short-lived due to emerging therapies and changing treatment paradigms. This analysis evaluates Telaprevir's investment potential, market landscape, competitive dynamics, and future financial prospects within evolving HCV therapeutics.

---

Introduction

• Chemical & Pharmacological Profile

  • Generic Name: Telaprevir
  • Drug Class: NS3/4A protease inhibitor
  • Approval Date: May 2011 (FDA)
  • Indication: Chronic hepatitis C genotype 1
  • Manufacturers: Vertex Pharmaceuticals (initial), later others in generics

• Market Life Cycle

  • Initial Launch: Significant market share (peak revenue in 2012)
  • Decline: Rapid phase-out post-introduction of direct-acting antivirals (DAAs) like sofosbuvir (Sovaldi), ledipasvir/sofosbuvir (Harvoni)

---

Investment Scenario Overview

Aspect	Details
Historical Revenue Peak	~$1.1 billion (2012; Vertex Pharmaceuticals)
Market Decline	Over 70% decline post-2014 with advent of newer DAAs
Current Market Status	No current marketed formulations; retired from pipeline
Generic Availability	Limited, given patent expirations and market shifts
Patent Status	Patent expired in 2018; no active exclusivity

Investment Outlook Summary
Given the obsolescence of Telaprevir due to advances in HCV therapy, direct investment opportunities predominantly exist within the context of historical analysis or in the context of assets with residual patent or IP rights, such as formulation patents or combination therapy patents. Current commercialization potential is minimal.

---

Market Dynamics

Historical Market Context

Year	Market Share & Revenue	Key Competitors & Substitutes
2011	Launch; rapid adoption in combination regimens	Boceprevir (Merck), interferon-based therapies
2012	Peak revenue (~$1,099 million); dominant within protease inhibitors	Sofosbuvir (Gilead), ledipasvir, daclatasvir
2014	Sharp revenue decline (>70%) due to DAAs' efficacy	Gilead's Sovaldi, Harvoni, Epclusa, and newer DAAs

Drivers and Restraints

Drivers	Restraints
High cure rates with DAAs	Patent expirations of antivirals
Shorter treatment durations	Limited or no new formulations of Telaprevir
High efficacy in genotype 1	Development of more convenient, interferon-free regimens
Initial Clinical success	Safety and side effect concerns (rash, anemia)

Transition in Market Dynamics

• The market has transitioned from protease inhibitors like telaprevir to all-oral, interferon-free regimens.
• Revenue and market share for protease inhibitors have significantly declined.
• Entry barriers for new stakeholders now favor organizations with innovative DAA portfolios.

---

Financial Trajectory and Projections

Time Horizon	Scenario	Key Assumptions & Comments	Projected Outcome
Short-term (1-3 yrs)	Asset liquidation or licensing	Patent expired; limited residual value; potential licensing of pipeline assets	Marginal or negligible revenues; licensing royalties possible
Medium-term (4-7 yrs)	Asset market devaluation	Market saturation with generics; no new formulations	Zero or negative revenue trajectory for Telaprevir assets
Long-term (>7 yrs)	Potential niche or legacy use	Rare residual use in specific populations or research	Minimal to no commercial significance

Comparison to Emerging HCV Therapies

Parameter	Telaprevir	Sofosbuvir & Co-Formulations
Market Entry Year	2011	2013–2014
Regulatory Approval	Yes	Yes
Market Status	Discontinued	Dominant, expanding
Efficacy Rates	~75% in genotype 1 (with interferon)	>95% in all genotypes with interferon-free regimens
Treatment Duration	12–24 weeks	8–12 weeks

---

Legal & Patent Landscape

Patent Type	Expiry Date	Implication
Composition of Matter Patent	2018	Limited to specific formulations
Method of Use Patents	Varies (expired or active)	Limited residual protections
Pipeline Patents	Not applicable	No active pipeline assets of note

---

Portfolio & Licensing Opportunities

Despite obsolescence, residual IP rights, formulations, and combination patents may offer licensing or strategic acquisition opportunities within niche markets such as:

• Research use
• Legacy treatment kits
• Formulation patent licensing to generic manufacturers

---

Comparison: Telaprevir vs. Key Competitors (Table)

Attribute	Telaprevir	Simeprevir (Janssen)	Boceprevir (Merck)	Sofosbuvir (Gilead)
Approval Year	2011	2013	2011	2013
Market Peak Revenue	~$1.1 billion	Not disclosed publicly	Similar to telaprevir	Billions (aggregated)
Market Status	Phased out	Limited, niche markets	Discontinued	Leading in market
Main Therapeutic Use	Genotype 1 HCV with interferon	Genotype 1 HCV	Genotype 1 HCV	All genotypes (regimens)

---

Regulatory & Policy Environment

• Patents & Exclusivity: Patent expiration in 2018 for key patent rights, removing exclusivity incentives.
• Generic Entry Policies: WTO TRIPS flexibilities enable generics post patent expiry.
• Pricing & Reimbursement: Declined sharply, with payers favoring newer, more effective DAA therapies.

---

Insights and Strategic Recommendations

• Investment in Telaprevir-based assets is historically viable only for legacy rights, patents, or niche applications.
• No substantial growth prospects; market is saturated with generics and advanced therapies.
• Focus should shift to the valuation of residual IP rights or licensing opportunities.

---

Key Takeaways

• Market Decline: Telaprevir's revenue sharply declined post-2014 due to emergence of interferon-free DAA regimens.
• Patent & Formulation Expiry: Patents expired in 2018, leading to limited exclusivity.
• Investment Perspective: Limited near-term or medium-term financial opportunities; suitable mainly for IP licensing or legacy asset management.
• Competitive Landscape: Dominated by more effective, safer, and shorter-course DAAs.
• Future Outlook: Minimal; emphasis should be on portfolio valuation or licensing rather than direct commercialization.

---

FAQs

1. What caused Telaprevir's market decline?
The advent of highly effective, shorter-duration, interferon-free direct-acting antivirals, such as sofosbuvir and ledipasvir, rendered Telaprevir obsolete, leading to a rapid revenue decline.

2. Are there any ongoing patents or exclusivities for Telaprevir?
No; all key patents expired by 2018, opening the market to generics and diminishing proprietary revenue streams.

3. Can Telaprevir be repositioned for any niche market?
Potentially for research or restricted use in specific populations, but such opportunities are limited and unlikely to generate significant revenue.

4. How does the current competitive environment affect potential investments?
The high competition from generic formulations and advanced DAAs makes new investments in Telaprevir assets unattractive, unless tied to residual IP licensing or niche applications.

5. What lessons can pharma investors learn from Telaprevir's market trajectory?
Early dominance followed by rapid obsolescence underscores the importance of innovation, lifecycle planning, and vigilant adaptation to evolving therapeutic standards.

---

References

1. FDA Approval Package for Telaprevir [1].
2. Vertex Pharmaceuticals Annual Reports (2012–2014) [2].
3. Market data: IQVIA, 2022 [3].
4. Patent Expiry Information (European Patent Office, 2018) [4].
5. WHO Treatment Guidelines for Hepatitis C (2018) [5].

---

This report offers a comprehensive corporate and market analysis of Telaprevir, guiding strategic decision-making for investors and stakeholders aligned with the evolving landscape of HCV therapeutics.